Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Lymphocyte Activation
100%
Renal Cell Carcinoma
100%
Putative Drug Targets
100%
Antibody-drug Conjugate
100%
CD70
100%
Activation Antigens
100%
Auristatin
27%
Metastatic Renal Cell Carcinoma (mRCC)
18%
Renal Carcinoma Cells
18%
Phenylalanine
18%
Disease Progression
9%
Unmet Medical Need
9%
New Markers
9%
Cytotoxicity
9%
Cell Cycle Arrest
9%
Treatment Strategy
9%
Carcinoma Cell Lines
9%
Aggressive Disease
9%
Xenograft Model
9%
Drug Delivery
9%
Tumor Cell Death
9%
Therapeutic Modalities
9%
Clear Cell
9%
Drug Release
9%
Endolysosomal System
9%
Cytotoxic Activity
9%
Drug Target
9%
Enhanced Cytotoxicity
9%
Papillary
9%
Antibody-based Therapeutics
9%
Subcellular Compartments
9%
Metastatic Site
9%
M Phase
9%
Advanced Renal Cell Carcinoma
9%
Tumor Necrosis Factor Superfamily
9%
Antibody Conjugates
9%
In Vitro Cytotoxicity
9%
Microtubule Network
9%
Phenylenediamine
9%
Antitubulin Agents
9%
Lymphocyte Activation Markers
9%
Subcellular Trafficking
9%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Antibody-Drug Conjugate
100%
Lymphocyte Activation
100%
CD70 Antigen
100%
Cytotoxicity
57%
Phenylalanine
28%
Kidney Metastasis
28%
In Vitro
14%
Microtubule
14%
Disease Exacerbation
14%
Tumor Necrosis Factor
14%
Xenograft
14%
Carcinoma Cell
14%
Tumor Cell
14%
Cell Cycle Arrest
14%
Therapeutic Modality
14%
Cell Killing
14%
Clear Cell
14%
Internalization
14%
Tubulin
14%
Cell Cycle Checkpoint
14%
Renal Cell Carcinoma Cell Line
14%
Phenylenediamine
14%
Antibody Conjugate
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Antibody Drug Conjugate
100%
CD70 Antigen
100%
Cytotoxicity
50%
Phenylalanine
25%
Kidney Metastasis
25%
Disease Exacerbation
12%
Neoplasm
12%
Tumor Necrosis Factor
12%
Drug Release
12%
Phenylenediamine
12%
Tubulin
12%
Antibody Conjugate
12%
Diseases
12%